Search
quizartinib (Vanflyta)
Indications:
- adults with acute myeloid leukemia (AML) that carries the FLT3-ITD genetic mutation [1]
- for use in combination with standard chemotherapy (cytarabine + anthracycline) induction followed by cytarabine consolidation & as maintenance monotherapy afterwards, in adults whose tumors express FLT3-ITD
*FDA-approved
Contraindications:
- maintenance monotherapy after allogeneic hematopoietic stem cell transplantation
Mechanism of action:
- targets internal tandem duplication (ITD) in mutated FLT3*
* this FLT3 mutation is associated with a higher relapse risk shorter survival
- ~1/4 of AML patients carry the mutation
* median overall survival among patients on standard chemotherapy + quizartinib is 32 months vs 15 months with standard chemotherapy + placebo
General
small inhibitory antineoplastic agent (ib drug)
References
- Otto MA
FDA Approves Quizartinib for Newly Diagnosed AML.
Medscape. July 20, 2023
https://www.medscape.com/viewarticle/994618